VRX stock is up nice today. It's at a 6 month high. Interesting given the news about Allergan being sold to Acatvis.
If it were at an all time high, I would have said so. More important is that VRX is moving forward. Allergan will be gone and forgotten soon.
from benzinga Activist hedge fund ValueAct Capital Management, run by Jeffrey Ubben, plans to raise up to $1.5 billion in new funds. After roughly three years without bringing in new capital, the fund could use the proceeds to either increase the size of preexisting bets or open new positions. One thing is quite certain, though: ValueAct invests with a longer term perspective than some of its peers, and can commit to multi-year investments. But, where could the new money go? As many investors already know, Ubben is quite bullish on Valeant Pharmaceuticals Intl Inc VRX 2.04%. As the largest hedge fund shareholder of record, ValueAct has been increasing its exposure to the company over the fourth quarter.
Why would you want stock in a company Trying 3 times to get approval for a useless compound .....Wait they would tell us to invest all our money in a dry eye technology that by the time we get approval it would be outdated... Wait they can convince us to study botox for usless indications..... Woops but there's no-one here in marketing or R&D or anywhere come to think of it...